Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials

Successful SARS-CoV-2 inactivation allows its safe use in Biosafety Level 2 facilities, and the use of the whole viral particle helps in the development of analytical methods and a more reliable immune response, contributing to the development and improvement of in vitro and in vivo assays. In order...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Mariana Pierre de Barros, Linhares, José Henrique Rezende, dos Santos, Tiago Pereira, Pereira, Renata Carvalho, Santos, Renata Tourinho, da Silva, Stephanie Almeida, Souza, Marta Cristina de Oliveira, da Silva, Juliana Fernandes Amorim, Trindade, Gisela Freitas, Gomes, Viviane Silva, Barreto-Vieira, Débora Ferreira, Carvalho, Milena Mouta Verdan França, Ano Bom, Ana Paula Dinis, Gardinali, Noemi Rovaris, Müller, Rodrigo, Alves, Nathalia dos Santos, Moura, Luma da Cruz, Neves, Patrícia Cristina da Costa, Esteves, Gabriela Santos, Schwarcz, Waleska Dias, Missailidis, Sotiris, Mendes, Ygara da Silva, de Lima, Sheila Maria Barbosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386713/
https://www.ncbi.nlm.nih.gov/pubmed/37515173
http://dx.doi.org/10.3390/v15071486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386713/
https://www.ncbi.nlm.nih.gov/pubmed/37515173
http://dx.doi.org/10.3390/v15071486

Ejemplares similares